Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 15/20 | 0.64 |
| ▸ | DRD2 | P14416 | 13/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839391 | 0.86 | DRD3 (0.63) | DRD3DRD2KCNH2 | |
| SCHEMBL4767819 | 0.85 | DRD3 (0.64) | DRD3DRD2KCNH2 | |
| SCHEMBL4836950 | 0.84 | DRD3 (0.53) | DRD3DRD2KCNH2 | |
| SCHEMBL4763624 | 0.83 | DRD3 (0.51) | DRD3DRD2KCNH2 | |
| SCHEMBL4769845 | 0.83 | DRD3 (0.65) | DRD3DRD2KCNH2 | |
| SCHEMBL4772428 | 0.83 | DRD3 (0.59) | DRD3DRD2KCNH2 | |
| SCHEMBL4769841 | 0.82 | DRD3 (0.66) | DRD3DRD2KCNH2 | |
| SCHEMBL4767832 | 0.82 | DRD3 (0.68) | DRD3DRD2KCNH2 | |
| SCHEMBL4773219 | 0.82 | DRD3 (0.56) | DRD3DRD2KCNH2 | |
| SCHEMBL4770366 | 0.81 | DRD3 (0.57) | DRD3DRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429579-B2 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM, PLC (GB) | 2008-09-30 | — | — | US | disclosed |
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM PLC (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | DRD3, DRD2, DRD1 | DRD3 1/4885DRD2 2/4885KCNH2 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.